PureTech Health (PRTC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key achievements and financial highlights

• Announced strong momentum into 2025, driven by positive phase IIb data for deupirfenidone in IPF and major corporate milestones, including the $14B acquisition of Karuna Therapeutics and FDA approval of Cobenfy.

• Launched Seaport Therapeutics in 2024, raising $325M from top-tier investors, further strengthening the balance sheet and self-funded R&D model.

• Ended 2024 with $365M in cash, supporting ongoing innovation and program advancement.

R&D strategy and portfolio structure

• Employs a hub-and-spoke R&D model, focusing on de-risked drug discovery using validated molecules with unmet patient needs.

• Over 80% clinical trial success rate in the past 15 years; three FDA-approved products originated from the platform.

• Portfolio includes wholly owned programs and founded entities, with equity, milestones, and royalty streams providing capital.

Deupirfenidone phase IIb clinical trial results

• Deupirfenidone, a deuterium-modified pirfenidone, showed strong efficacy and favorable tolerability in IPF patients.

• Achieved primary and key secondary endpoints, with the 825mg TID dose slowing lung function decline to near-normal levels for healthy older adults.

• Statistically significant differences from placebo were observed, with robust results confirmed by both Bayesian and frequentist analyses.

• Over 90% of patients completing six months enrolled in the open-label extension, with durable effects maintained up to 52 weeks.

• Plans to initiate phase III trial before year-end, pending regulatory feedback.